GlassScriptPhysician profile
Riyana Khalifa
NPI 1215613591
$2,288.35
in general payments reported to CMS, 2019-2025
20 companies · $789 in 2025
The $789 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $141 · 2024: $1,358 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $453.22 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $372.22 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $305.90 | 2023-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.59 | 2024-2025 | Jardiance |
| Antares Pharma, INC. | $104.23 | 2024-2025 | Xyosted |
| Abbvie INC. | $94.04 | 2024 | |
| Tandem Diabetes Care, INC. | $79.48 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $77.23 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $72.28 | 2024-2025 | |
| Corcept Therapeutics | $71.90 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $67.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Chiesi USA, INC. | $64.81 | 2024-2025 | Mycapssa |
| Radius Health, INC. | $64.17 | 2023-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $49.00 | 2024-2025 | Strensiq |
| Beta Bionics, INC. | $36.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.70 | 2024-2025 | Nexletol |
| Kyowa Kirin, INC. | $34.79 | 2025 | |
| Ascendis Pharma Endocrinology INC | $33.57 | 2025 | Yorvipath |
| Astellas Pharma US INC | $22.41 | 2025 | Veozah |
| Insulet Corporation | $21.07 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riyana Khalifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.